Effect of Denosumab and Alendronate on osteoporosis in hemodialysis patients :a randomized controlled trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Alendronic acid (Primary) ; Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 19 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2016 Planned number of patients changed from 40 to 80.
- 14 Jul 2016 New trial record